Cargando…
Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina
INTRODUCTION: The KEYNOTE-054 trial demonstrated that adjuvant pembrolizumab improves recurrence-free survival in completely resected stage III melanoma versus watchful waiting (hazard ratio [HR] = 0.57; 98.4% confidence interval [CI], 0.43–0.74). We evaluated the cost-effectiveness of pembrolizumab...
Autores principales: | Wurcel, Victoria, Scherrer, Emilie, Aguiar-Ibanez, Raquel, Altuna, Juan Ignacio, Carabajal, Fernando, Jain, Shrishti, Baluni, Gargi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140053/ https://www.ncbi.nlm.nih.gov/pubmed/33624271 http://dx.doi.org/10.1007/s40487-021-00142-8 |
Ejemplares similares
-
Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection
por: Lopez-Vinueza, Cesar, et al.
Publicado: (2023) -
Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
por: Wurcel, Victoria, et al.
Publicado: (2021) -
An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma
por: Lorenzi, Maria, et al.
Publicado: (2019) -
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA
por: Bensimon, Arielle G., et al.
Publicado: (2020) -
Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab
por: Takamori, Shinkichi, et al.
Publicado: (2021)